Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia with Anal Cancer Risk in Persons Living with HIV in the United States and Canada by Hernandez-Rami­rez, R.U. et al.
Received 7 January 2019; editorial decision 18 April 2019; accepted 22 April 2019; published 
online May 8, 2019.
aPresent affiliation: Department of Biostatistics, Yale School of Public Health, Yale School of 
Medicine, New Haven, Connecticut.
Correspondence: R. U. Hernández-Ramírez, Department of Biostatistics, Yale School of Public 
Health, Yale School of Medicine, New Haven, CT 06520-8034 
(raul.hernandezramirez@yale.edu
Association of Immunosuppression and Human 
Immunodeficiency Virus (HIV) Viremia With Anal 
Cancer Risk in Persons Living With HIV in the United 
States and Canada
Raúl U. Hernández-Ramírez,1,a Li Qin,2 Haiqun Lin,3 Wendy Leyden,4 Romain S. Neugebauer,4 Keri N. Althoff,5 Nancy A. Hessol,6 Chad J. Achenbach,7 
John T. Brooks,8 M. John Gill,9 Surbhi Grover,10 Michael A. Horberg,11 Jun Li,12 W. Christopher Mathews,13 Angel M. Mayor,14 Pragna Patel,8  
Charles S. Rabkin,15 Anita Rachlis,16 Amy C. Justice,2,17,18 Richard D. Moore,19 Eric A. Engels,15 Michael J. Silverberg,4 and Robert Dubrow20; for the North 
American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS
1Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale School of Medicine, 2Department of Internal Medicine, Yale School of Medicine, and 3Department of Biostatistics, 
Yale School of Public Health, Yale School of Medicine, New Haven, Connecticut; 4Division of Research, Kaiser Permanente Northern California, Oakland; 5Department of Epidemiology, Johns 
Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; 6Department of Clinical Pharmacy, University of California, San Francisco; 7Division of Infectious Diseases, 
Northwestern University Feinberg School of Medicine, Chicago, Illinois; 8Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; 9Department of Medicine, 
University of Calgary, Alberta, Canada; 10Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia; 11Mid-Atlantic Permanente Research Institute, 
Kaiser Permanente Mid-Atlantic States, Rockville, Maryland; 12Epidemiology Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; 13Department 
of Medicine, University of California, San Diego; 14Retrovirus Research Center, Department of Medicine, Universidad Central del Caribe School of Medicine, Bayamon, Puerto Rico; 15Infections and 
Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 16Sunnybrook Health Sciences Centre and Department of Medicine, 
University of Toronto, Ontario, Canada; 17Department of Health Policy and Management, Yale School of Public Health, Yale School of Medicine, New Haven, Connecticut, and 18Research Service, 
Veterans Affairs Connecticut Healthcare System, West Haven; 19Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 20Department of Environmental 
Health Sciences, Yale School of Public Health, Yale School of Medicine, New Haven, Connecticut
Background. People living with human immunodeficiency virus (HIV; PLWH) have a markedly elevated anal cancer risk, 
largely due to loss of immunoregulatory control of oncogenic human papillomavirus infection. To better understand anal cancer de-
velopment and prevention, we determined whether recent, past, cumulative, or nadir/peak CD4+ T-cell count (CD4) and/or HIV-1 
RNA level (HIV RNA) best predict anal cancer risk.
Methods. We studied 102 777 PLWH during 1996–2014 from 21 cohorts participating in the North American AIDS Cohort 
Collaboration on Research and Design. Using demographics-adjusted, cohort-stratified Cox models, we assessed associations be-
tween anal cancer risk and various time-updated CD4 and HIV RNA measures, including cumulative and nadir/peak measures 
during prespecified moving time windows. We compared models using the Akaike information criterion.
Results. Cumulative and nadir/peak CD4 or HIV RNA measures from approximately 8.5 to 4.5 years in the past were generally 
better predictors for anal cancer risk than their corresponding more recent measures. However, the best model included CD4 nadir 
(ie, the lowest CD4) from approximately 8.5 years to 6 months in the past (hazard ratio [HR] for <50 vs ≥500 cells/µL, 13.4; 95% 
confidence interval [CI], 3.5–51.0) and proportion of time CD4 <200 cells/µL from approximately 8.5 to 4.5 years in the past (a cu-
mulative measure; HR for 100% vs 0%, 3.1; 95% CI, 1.5–6.6).
Conclusions. Our results are consistent with anal cancer promotion by severe, prolonged HIV-induced immunosuppression. 
Nadir and cumulative CD4 may represent useful markers for identifying PLWH at higher anal cancer risk.
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Anal cancer risk is markedly elevated among people living 
with human immunodeficiency virus (HIV; PLWH), especially 
those with AIDS and men who have sex with men (MSM) [1, 2]. 
Immunosuppression is associated with persistent oncogenic 
human papillomavirus (HPV) infection, which promotes de-
velopment of anal high-grade squamous intraepithelial lesions/
anal intraepithelial neoplasia 2-3 (HSIL/AIN2-3) but may play 
a lesser role in HSIL/AIN2-3 progression to anal cancer [3–6]. 
Despite improvements in immune function after the introduc-
tion of effective antiretroviral therapy (ART) in 1996, most 
studies of anal cancer incidence trends in PLWH have reported 
an increase or no change over time [7–15], with an apparent de-
cline in recent years [1, 2]. Among non-AIDS–defining cancers, 
anal cancer exhibits the highest relative risk in PLWH compared 
with the general population [1].
Immunosuppression and HIV viremia have been associated 
with anal cancer risk, but the time courses over which they exert 
their effects are unclear. Increased anal cancer risk has been as-
sociated with lower CD4+ T-cell count (CD4) [8–10, 16–26] 
and higher HIV-1 RNA level (HIV RNA) [18, 24, 26–28], even 
after mutual adjustment [18, 24, 26, 27]. It remains unknown 
whether risk is driven by recent, past, cumulative, or nadir/
peak (ie, the lowest CD4 and the highest HIV RNA) CD4 and/
or HIV RNA. Evidence suggests that past (ie, 6–7 years before 
diagnosis) [23], cumulative (ie, duration with CD4 <200 cells/
µL) [18], and nadir (ie, the lowest CD4 ever or before ART ini-
tiation) [8, 23, 24, 26] CD4 are better risk predictors than recent 
CD4 and that cumulative HIV RNA (eg, duration with HIV 
RNA >100 000 copies/mL) is a better predictor than recent HIV 
RNA [18, 27].
To contribute to our understanding of anal carcinogenesis 
and help tailor approaches to prevention, we aimed to deter-
mine whether recent, past, cumulative, or nadir/peak CD4 
and HIV RNA measures best predict anal cancer risk among 
PLWH in the North American AIDS Cohort Collaboration on 
Research and Design (NA-ACCORD) [29].
METHODS
Study Sample
Our study population included PLWH (aged ≥18 years) from 21 
cohorts in the United States and Canada that contributed data, 
including cancer diagnoses, to the NA-ACCORD (1996–2014) 
[15, 29]. Cohorts submitted demographic and clinical data 
using standardized collection methods. Incident invasive anal 
cancers were validated using a standardized process of either 
cancer registry linkage or manual review of medical records and 
pathology reports [15]. Institutional review board approval was 
obtained for each cohort.
Follow-up started at the latest of the following dates: 1 
January 1996, NA-ACCORD entry (first of 2 HIV primary care 
visits ≤1 year apart), cohort-specific start for cancer reporting, 
18th birthday, or 360 days before the later of the first CD4 or 
HIV RNA measurement. Follow-up ended at the earliest of 
anal cancer diagnosis, cohort-specific end for cancer reporting, 
death, or 540 days after the earlier of the last CD4 or HIV RNA 
measurement. We excluded persons with <2 CD4 or <2 HIV 
RNA measurements or with follow-up ≤180 days.
Time-updated CD4 and HIV RNA Measures
We estimated CD4 and HIV RNA values at 30-day intervals 
using observed laboratory measurements, as previously 
described (Supplementary Methods) [30]. Based on these 
estimated values, we constructed time-updated CD4 and HIV 
RNA measures that were all lagged by at least 180 days to reduce 
the possibility of reverse causality. Thus, we examined CD4 and 
HIV RNA lagged by 180  days (approximately 6  months; de-
fined as “recent”) and then by longer lag (lagged by 360  day 
[approximately 1 year] increments from 540 to 1620 days, and 
by 720  day [approximately 2  years] increments from 1620 to 
3060 days).
We also constructed lagged cumulative and nadir/peak meas-
ures during prespecified moving time windows. Cumulative 
measures were CD4 or HIV RNA average (ie, normalized by 
time) and proportion of time CD4 <200 cells/µL or HIV RNA 
>500 copies/mL. Nadir/peak measures were lowest CD4 and
highest HIV RNA. The duration of the “early” (more distant
past) and “late” (more recent past) windows was 1440 days (ap-
proximately 4 years). The early window was lagged by 1620 days 
(ie, covered approximately 8.5 to approximately 4.5 years in the
past), and the late window was lagged by 180 days (ie, covered
approximately 4.5 years to approximately 6 months in the past).
The “overall” (early and late combined) window (2880 days du-
ration; approximately 8  years) covered 3060 to 180  days (ap-
proximately 8.5 years to approximately 6 months) in the past.
Analyses of these various measures were restricted to per-
sons with follow-up duration greater than the examined lag 
or window start (eg, the late window [starting at 1620 days in 
the past] can only be assessed among persons with follow-up 
>1620  days). Thus, the analyzed sample size decreased with
increasing lag or amount of time in the past of the window start.
Statistical Analyses
We assessed associations between CD4 and HIV RNA meas-
ures and anal cancer risk using cohort-stratified Cox regression 
models with follow-up time as the time scale using counting 
process syntax [31] to account for time-varying covariates 
updated at 30-day intervals. We modeled these measures as cat-
egorical variables (calculating likelihood ratio global P values) 
and as continuous variables to test for trends (Ptrend).
To identify a final model with the most robust independent 
CD4 and/or HIV RNA predictors, we compared models using 
the Akaike information criterion (AIC), which accounts 
for both model fit and parsimony. A  smaller AIC indicates a 
better model; a difference in AIC that is >10 between models 
is considered meaningful [32]. Models being compared must 
use the same participant set. To make valid comparisons across 
all models, we examined AICs among persons with follow-up 
>3060 days (N = 34 625; anal cancer cases = 170). To choose
CD4 measures for further testing, we compared separate models 
including each CD4 measure individually. Then, to select the
best CD4 measure(s), we compared models that included the
measures chosen for further testing, 2 at a time in the same
model. We did the same for HIV RNA measures. To develop
our final model, we compared models including combinations
of the best CD4 and/or HIV RNA measures in the same model.
All models were adjusted for sex, race/ethnicity, and baseline 
age and calendar period. We did not adjust for history of AIDS 
due to its expected high collinearity with CD4 nadir and other 
CD4 or HIV RNA measures. In the primary analysis, we did 
not adjust for HIV risk group or smoking due to a large number 
of unknowns, and we did not adjust for ART use because ART 
initiation during the study period was affected by prior CD4 
[33]. In separate sensitivity analyses, we adjusted for HIV risk 
group, smoking, and cumulative ART use in our final model 
and assessed whether HIV risk group modified the association 
between the predictors and anal cancer risk in our final model 
(Supplementary Methods).
We used SAS version 9.4 (SAS Institute Inc., Cary, NC) to 
perform analyses, and a 2-sided P value of .05 to determine sta-
tistical significance.
RESULTS
Among 122 840 PLWH included in the 21 NA-ACCORD cohorts, 
102 777 persons were eligible for this study (Table 1). Excluded 
persons had <2 CD4 or <2 HIV RNA measurements (n = 13 701) 
or no follow-up time (n = 6362). Most eligible persons were male 
(85%), of white (44%) or black race/ethnicity (40%), and started 
follow-up during the period 1996–2003 (57%). At baseline, most 
were aged ≥40 years (57%) and ART naive (67%), with CD4 ≥200 
cells/µL (69%) and HIV RNA >500 copies/mL (70%). Persons 
diagnosed with anal cancer (n = 492) included a larger propor-
tion of males (96%), persons of white race/ethnicity (61%), and 
persons who started follow-up during the period 1996–1999 
(55% vs 32%). At baseline, they were more likely to be aged 
≥40 years (64%) but less likely to be ART naive (57%) or to have 
a CD4 ≥200 cells/µL (49%).
Selection of Individual CD4 or HIV RNA Measures for Further Testing
In separate models, anal cancer risk was significantly associ-
ated with each CD4 and HIV RNA measure, except HIV RNA 
lagged by 180 and 540 days (Tables 2–4). Models with stronger 
associations (ie, higher hazard ratios [HRs]) and lower AICs were 
largely concentrated in single measures lagged by ≥1260 days (ie, 
occurring approximately 8.5 to approximately 3.5  years in the 
past) and in early cumulative and nadir/peak measures (ie, from 
3060 to 1620 days [approximately 8.5 to approximately 4.5 years] 
in the past). Based on the results from separate models and 
models that included 2 cumulative or nadir/peak measures of the 
same type for CD4 (eg, early and late CD4 average in the same 
model) and HIV RNA, respectively (Supplementary Results; 
Supplementary Tables 1 and 2), we chose several CD4 measures 
(1620 day lag, early and overall average, early and overall propor-
tion of time CD4 <200 cells/ µL, and early and overall nadir) and 
HIV RNA measures (3060 day lag, early average, and early peak) 
for further consideration.
Selection of Best CD4 Predictor(s)
We fit models including the CD4 measures chosen for further 
consideration above, 2 at a time. The model with both overall 
Table 1. Baseline Characteristics of Study Sample, North American AIDS 
Cohort Collaboration on Research and Design, 1996–2014
Characteristic
All (N = 102 777)
Anal Cancer Cases 
(n = 492)
n (%) n (%)
Sex
 Male 87 059 (84.7) 470 (95.5)
 Female 15 718 (15.3) 22 (4.5)
Race/ethnicity
 Black 41 331 (40.2) 156 (31.7)
 White 44 741 (43.5) 302 (61.4)
 Hispanic 6934 (6.8) 13 (2.6)
 Other 4100 (4.0) 9 (1.8)
Unknown, imputed 5671 (5.5) 12 (2.4)
Age, y
 18–29 13 107 (12.8) 18 (3.7)
 30–39 30 890 (30.1) 160 (32.5)
 40–49 35 930 (35.0) 188 (38.2)
 ≥50 22 850 (22.2) 126 (25.6)
Calendar period
 1996–1999 32 426 (31.6) 272 (55.3)
 2000–2003 25 949 (25.2) 133 (27.0)
 2004–2007 19 870 (19.3) 55 (11.2)
 2008–2011 18 287 (17.8) 28 (5.7)
 2012–2014 6245 (6.1) 4 (0.8)
Combination antiretroviral therapy 
naive
 No 34 022 (33.1) 210 (42.7)
 Yes 68 755 (66.9) 282 (57.3)
CD4 count, cells/µL
 <50 11 259 (11.0) 87 (17.7)
50 to <100 6856 (6.7) 62 (12.6)
100 to <200 13 596 (13.2) 104 (21.1)
200 to <350 22 252 (21.7) 120 (24.4)
350 to <500 20 058 (19.5) 59 (12.0)
 ≥500 28 756 (28.0) 60 (12.2)
HIV RNA level, copies/mL
 ≤500 30 987 (30.1) 133 (27.0)
>500 to <10 000 20 738 (20.2) 113 (23.0)
10 000 to <100 000 30 394 (29.6) 138 (28.0)
≥100 000 20 658 (20.1) 108 (22.0)
HIV risk group
Injection drug use 12 695 (12.4) 33 (6.7)
Men who have sex with men 32 669 (31.8) 222 (45.1)
 Heterosexual 16 134 (15.7) 29 (5.9)
 Other 2089 (2.0) 4 (0.8)
Unknown, imputeda 5636 (5.5) 14 (2.9)
Unknown, not imputeda 33 554 (32.6) 190 (38.6)
Smoking status
 Ever 54 994 (53.5) 350 (71.1)
 Never 19 491 (19.0) 102 (20.7)
Unknown, imputeda 15 711 (15.3) 19 (3.9)
Unknown, not imputeda 12 581 (12.2) 21 (4.3)
Abbreviation: HIV, human immunodeficiency virus.
aWe imputed HIV risk group and smoking status for persons with unknown values, except 
for cohorts with a high proportion of unknowns, or, for smoking, with all the knowns being 
smokers.
CD4 nadir and early proportion of time CD4  <200 cells/µL 
showed an AIC that was meaningfully lower than any other 
model containing 1 or 2 CD4 measures (data not shown). These 
2 measures were highly correlated (Supplementary Table  3; 
Spearman correlation coefficient, –0.77; P <  .0001), as were 
most cumulative and nadir CD4 measures.
Selection of the Best HIV RNA Predictor(s)
We fit models including the HIV RNA measures chosen for 
further consideration above, 2 at a time. None of these models 
showed an AIC that was meaningfully lower than that for early 
HIV RNA average alone, the single HIV RNA measure with 
the lowest AIC (data not shown). Although the AIC differ-
ence between separate models for early HIV RNA average and 
early HIV RNA peak was not meaningful (Table 4), when they 
were included in the same model, only early HIV RNA average 
remained significant (global P = .0061).
Final Model
We compared models with combinations of the best CD4 
predictors (overall nadir and early proportion of time CD4 <200 
cells/µL) and HIV RNA predictors (early average; Table 5). The 
model with the 2 CD4 measures prevailed as the model with 
the lowest AIC. Furthermore, early HIV RNA average lost its 
significance when added to this model. Thus, our final model 
included overall CD4 nadir (HR for <50 vs ≥500 cells/µL, 13.4; 
95% confidence interval [CI], 3.5–51.0; Ptrend < .0001) and early 
proportion of time CD4 <200 cells/µL (HR for entire vs no time, 
3.1; 95% CI, 1.5–6.6; Ptrend = .0030). In sensitivity analyses (data 
not shown), the HRs for these 2 measures did not meaningfully 
change after our final model was adjusted for HIV risk group, 
smoking, or cumulative ART use and were not significantly 
different between MSM and other/unknown HIV risk groups 
(P = .69 for overall CD4 nadir and P = .065 for early proportion 
of time CD4 <200 cells/µL).
The median overall CD4 nadir at the end of follow-up was 
137 cells/µL (interquartile range [IQR], 38–256) among anal 
cancer cases compared with 259 cells/µL (IQR, 134–401) among 
noncases. The median time from CD4 nadir to anal cancer di-
agnosis was 4.9 years (IQR, 3.0–7.4).
DISCUSSION
Among PLWH in the United States and Canada, the most ro-
bust independent predictors for anal cancer risk were overall 
CD4 nadir (ie, lowest CD4 from approximately 8.5 years to ap-
proximately 6 months in the past) and early cumulative CD4 
(ie, proportion of time CD4 <200 cells/µL from approximately 
8.5 to approximately 4.5  years in the past). HIV RNA meas-
ures did not further improve anal cancer risk prediction. Our 
results confirmed the association between HIV-related immu-
nosuppression and anal cancer risk [8–10, 16–26]; suggested 
a key role for severe, prolonged immunosuppression in anal 
carcinogenesis; and favored a greater role of immunosuppres-
sion at earlier compared with late phases of anal carcinogenesis.
Similar to our study, a previous study found nadir and cu-
mulative CD4 to be independent predictors of anal cancer risk 
[25]. Other studies have found nadir [8, 9, 16, 19, 23, 24, 26] 
or cumulative CD4 [18, 21] to be associated with anal cancer 
risk and found nadir [8, 23, 24, 26], cumulative [18], and past 
[23] CD4 to be better predictors than recent CD4. Furthermore, 
PLWH with a prior AIDS diagnosis, which captures a history
of severe immunosuppression (ie, a low CD4 nadir), have an
elevated anal cancer risk compared to PLWH without AIDS [1].
In our study, based on AICs and strengths of association, 
single past CD4 measures (ie, lagged by approximately 3.5 to 
approximately 8.5 years) and early cumulative and nadir CD4 
measures (from approximately 8.5 to approximately 4.5  years 
in the past) were generally better predictors of anal cancer risk 
than more recent CD4 measures, with early proportion of time 
CD4 <200 cells/µL included in our final model. Furthermore, 
only early measures remained significant when both early and 
late CD4 measures of the same type were modeled together 
(Supplementary Table 1). Nevertheless, as overall CD4 nadir 
was highly correlated with both early and late CD4 nadir, it was 
difficult to definitively tease apart these 3 constructs. Moreover, 
besides capturing severity of immunosuppression, overall CD4 
nadir likely captured cumulative immunosuppression, as it was 
highly correlated with cumulative CD4 measures.
We and others have found cumulative HIV RNA measures 
to be significantly associated with anal cancer risk [18, 24, 26, 
27] and to be better predictors than recent HIV RNA [18, 27].
However, when we added early HIV RNA average to a model
with our 2 key CD4 predictors, it lost statistical significance and 
the model fit did not improve. These results suggest that the
HIV RNA effect was entirely mediated by its effect of lowering
CD4 [34], with no independent HIV RNA effect. In contrast,
the only other study to comprehensively evaluate different CD4
and HIV RNA measures determined both cumulative CD4 and
cumulative HIV RNA to be independent key predictors [18].
Prolonged immunosuppression-driven loss of control of on-
cogenic HPV infection is considered the primary mechanism 
that drives anal carcinogenesis in PLWH [3–5]. Lower CD4 
is associated with increased anal HPV infection prevalence 
and persistence, greater amounts of HPV DNA, more HPV 
types in anal specimens, higher incidence and prevalence of 
anal intraepithelial neoplasia, and faster progression to HSIL/
AIN2-3 [3, 4]. However, HIV-induced immunosuppression 
may not be critical for HSIL/AIN2-3 progression to anal cancer 
[3–6], and HPV-associated genetic instability and other factors 
(eg, smoking) that lead to genetic changes in HSIL/AIN2-3 may 
have a greater influence on progression [3, 4]. Our results gen-
erally supported this model, with early CD4 measures being 
better predictors for anal cancer risk than late CD4 measures. 
Nevertheless, our identification of overall CD4 nadir (ie, from 
Table 2. Recent and Past CD4 Count Measures and Anal Cancer Risk, North American AIDS Cohort Collaboration on Research and Design, 1996–2014
CD4 Count Measure (cells/µL) Anal Cancer Cases Hazard Ratio (95% Confidence Interval)a Global P Value (Akaike Information Criterion)b
180 d (approximately 6 mo) lag (ie, “recent”)
 <50 27 4.1 (2.7, 6.3) <.0001 (2603)
50 to <100 34 4.6 (3.1, 6.7) …
100 to <200 73 3.1 (2.3, 4.2) …
200 to <350 135 2.6 (2.0, 3.3) …
350 to <500 106 1.8 (1.4, 2.3) …
 ≥500 117 1.0 (ref) …
Per 50 cells/µLc … 0.91 (0.89, 0.93) …
540 d (approximately 1.5 y) lag 
 <50 34 5.8 (3.9, 8.7) <.0001 (2591)
50 to <100 27 3.7 (2.4, 5.7) …
100 to <200 88 3.8 (2.9, 5.1) …
200 to <350 113 2.2 (1.7, 2.9) …
350 to <500 92 1.6 (1.2, 2.1) …
 ≥500 106 1.0 (ref) …
Per 50 cells/µLc … 0.90 (0.88, 0.92) …
900 d (approximately 2.5 y) lag
 <50 25 4.6 (2.9, 7.2) <.0001 (2596)
50 to <100 32 4.6 (3.1, 6.9) …
100 to <200 79 3.6 (2.6, 4.8) …
200 to <350 98 2.0 (1.5, 2.7) …
350 to <500 74 1.4 (1.0, 1.8) …
 ≥500 98 1.0 (ref) …
Per 50 cells/µLc … 0.90 (0.88, 0.92) …
1260 d (approximately 3.5 y) lag
 <50 36 8.0 (5.4, 12.0) <.0001 (2584)
50 to <100 25 4.2 (2.7, 6.6) …
100 to <200 66 3.4 (2.4, 4.7) …
200 to <350 80 1.9 (1.4, 2.5) …
350 to <500 69 1.5 (1.1, 2.0) …
 ≥500 83 1.0 (ref) …
Per 50 cells/µLc … 0.89 (0.86, 0.91) …
1620 d (approximately 4.5 y) lag
 <50 33 9.5 (6.2, 14.7) <.0001 (2575)
50 to <100 28 6.0 (3.8, 9.5) …
100 to <200 58 3.8 (2.6, 5.4) …
200 to <350 65 1.9 (1.4, 2.8) …
350 to <500 74 2.1 (1.5, 2.9) …
 ≥500 62 1.0 (ref) …
Per 50 cells/µLc … 0.88 (0.86, 0.91) …
2340 d (approximately 6.5 y) lag
 <50 27 9.0 (5.6, 14.6) <.0001 (2581)
50 to <100 14 3.6 (2.0, 6.6) …
100 to <200 47 3.6 (2.4, 5.5) …
200 to <350 53 1.9 (1.3, 2.8) …
350 to <500 48 1.6 (1.1, 2.4) …
 ≥500 50 1.0 (ref) …
Per 50 cells/µLc … 0.88 (0.86, 0.91) …
3060 d (approximately 8.5 y) lag
 <50 13 6.3 (3.3, 12.2) <.0001 (2580)
50 to <100 18 6.6 (3.7, 11.9) …
100 to <200 37 4.2 (2.6, 6.8) …
200 to <350 47 2.5 (1.6, 3.9) …
350 to <500 23 1.2 (0.7, 2.0) …
 ≥500 32 1.0 (ref) …
Per 50 cells/µLc … 0.87 (0.84, 0.90) …
aEach measure was individually included in a cohort-stratified Cox model adjusted for sex, race/ethnicity, and baseline age and calendar period. The N and number of anal cancer cases used for the model 
of each measure was: 180 d lag (N = 102 777; number of anal cancer cases = 492), 540 d lag (94 458; 460), 900 d lag (79 882; 406), 1260 d lag (68 953; 359), 1620 d lag (60 006; 320), 2340 d lag (45 343; 
239), and 3060 d lag (34 625; 170).
bGlobal P value and Akaike information criterion from models among persons with follow-up >3060 days (N = 34 625; number of anal cancer cases = 170).
cPtrend < .0001.
approximately 8.5  years to approximately 6  months in the 
past) as a key predictor suggests a role for severe, prolonged 
immunosuppression in both HSIL/AIN2-3 development and 
progression.
HIV-encoded proteins may also contribute to HSIL/AIN2-3 
development by facilitating initial HPV infection [35] or by 
upregulating HPV oncogenes [5, 36]. Although our finding of 
no independent HIV RNA effect contradicts this hypothesis, 
HIV RNA may be an imperfect marker for viral protein effects.
ART’s role in preventing anal carcinogenesis is unclear [3–5]. If 
severe, prolonged immunosuppression in the presence of infection 
with oncogenic HPV types is a key risk factor in anal carcinogenesis, 
Table 3. Recent and Past Human Immunodeficiency Virus RNA Level Measures and Anal Cancer Risk, North American AIDS Cohort Collaboration on 
Research and Design, 1996–2014
Human Immunodeficiency Virus RNA Level Measure 
(copies/mL) Anal Cancer Cases
Hazard Ratio (95% Confidence 
Interval)a
Global P Value (Akaike Infor-
mation Criterion)b
180 d (approximately 6 mo) lag (ie, “recent”)
 ≤500 341 1.0 (ref) .14 (2643)
>500 to <10 000 66 0.9 (0.7, 1.2) …
10 000 to <100 000 59 1.0 (0.8, 1.3) …
≥100 000 26 1.3 (0.9, 1.9) …
Per log10 copies/mLc … 1.01 (0.93, 1.11) …
540 d (approximately 1.5 y) lag
 ≤500 288 1.0 (ref) .086 (2642)
>500 to <10 000 77 1.1 (0.8, 1.4) …
10 000 to <100 000 63 1.2 (0.9, 1.5) …
≥100 000 32 1.8 (1.2, 2.7) …
Per log10 copies/mLc … 1.13 (1.03, 1.23) …
900 d (approximately 2.5 y) lag
 ≤500 233 1.0 (ref) .013 (2638)
>500 to <10 000 74 1.2 (0.9, 1.6) …
10 000 to <100 000 70 1.5 (1.1, 1.9) …
≥100 000 29 2.0 (1.3, 2.9) …
Per log10 copies/mLc … 1.22 (1.11, 1.33) …
1260 d (approximately 3.5 y) lag
 ≤500 189 1.0 (ref) <.0001 (2624)
>500 to <10 000 70 1.3 (1.0, 1.7) …
10 000 to <100 000 70 1.7 (1.3, 2.3) …
≥100 000 30 2.5 (1.7, 3.7) …
Per log10 copies/mLc … 1.27 (1.16, 1.39) …
1620 d (approximately 4.5 y) lag
 ≤500 165 1.0 (ref) <.0001 (2627)
>500 to <10 000 61 1.1 (0.8, 1.5) …
10 000 to <100 000 62 1.6 (1.2, 2.1) …
≥100 000 32 2.8 (1.9, 4.2) …
Per log10 copies/mLc … 1.31 (1.19, 1.45) …
2340 d (approximately 6.5 y) lag
 ≤500 105 1.0 (ref) .0002 (2629)
>500 to <10 000 59 1.5 (1.1, 2.0) …
10 000 to <100 000 53 1.8 (1.3, 2.6) …
≥100 000 22 2.7 (1.7, 4.3) …
Per log10 copies/mLc … 1.32 (1.18, 1.48) …
3060 d (approximately 8.5 y) lag
 ≤500 66 1.0 (ref) <.0001 (2619)
>500 to <10 000 37 1.3 (0.9, 1.9) …
10 000 to <100 000 50 2.5 (1.7, 3.7) …
≥100 000 17 3.1 (1.8, 5.3) …
Per log10 copies/mLc … 1.49 (1.30, 1.70) …
aEach measure was individually included in a cohort-stratified Cox model adjusted for sex, race/ethnicity, and baseline age and calendar period. The N and number of anal cancer cases 
used for the model of each measure was: 180 d lag (N = 102 777; number of anal cancer cases = 492), 540 d lag (94 458; 460), 900 d lag (79 882; 406), 1260 d lag (68 953; 359), 1620 d lag 
(60 006; 320), 2340 d lag (45 343; 239), and 3060 d lag (34 625; 170).
bGlobal P value and Akaike information criterion from models among persons with follow-up >3060 days (N = 34 625; number of anal cancer cases = 170).
cPtrend < .0001, except for 180 d lag (Ptrend = .75) and 540 d lag (Ptrend = .0086).
Table 4. Cumulative and Nadir/Peak CD4 Count and Human Immunodeficiency Virus RNA Level Measures During Moving Time Windows and Anal Cancer 




(3060 to 1620 d in the Past) (1620 to 180 d in the Past) (3060 to 180 d in the Past)
Anal Cancer Cases HR (95% CI) Anal Cancer Cases HR (95% CI) Anal Cancer Cases HR (95% CI)
CD4 count average, cells/µL
 <50 10 12.2 (6.0, 24.8) 15 7.6 (4.3, 13.3) 8 20.7 (9.5, 45.0)
50 to <100 18 9.1 (5.1, 16.2) 24 5.4 (3.4, 8.6) 14 9.3 (5.0, 17.3)
100 to <200 28 3.7 (2.2, 6.1) 60 3.8 (2.7, 5.3) 30 4.4 (2.7, 7.2)
200 to <350 43 2.4 (1.5, 3.7) 74 2.0 (1.5, 2.8) 45 2.7 (1.7, 4.1)
350 to <500 36 1.7 (1.1, 2.7) 66 1.5 (1.1, 2.0) 35 1.6 (1.0, 2.6)
 ≥500 35 1.0 (ref) 81 1.0 (ref) 38 1.0 (ref)
Per 50 cells/µLb … 0.86 (0.83, 0.90) … 0.88 (0.86, 0.91) … 0.86 (0.83, 0.89)
 Global P value (AIC)c … <.0001 (2577) … <.0001 (2594) … <.0001 (2569)
Proportion of time CD4 count <200 cells/µL
 0.00 73 1.0 (ref) 148 1.0 (ref) 61 1.0 (ref)
>0.00 to 0.25 29 2.1 (1.4, 3.3) 44 1.7 (1.2, 2.5) 36 1.8 (1.2, 2.7)
>0.25 to 0.50 12 2.1 (1.1, 3.8) 24 2.3 (1.5, 3.5) 19 2.7 (1.6, 4.6)
>0.50 to 0.75 10 2.2 (1.2, 4.3) 26 3.2 (2.1, 4.8) 18 3.6 (2.1, 6.2)
>0.75 to <1.00 9 2.1 (1.1, 4.3) 32 4.1 (2.8, 6.0) 16 4.0 (2.3, 7.1)
1.00 37 7.9 (5.3, 11.9) 46 4.7 (3.4, 6.6) 20 10.3 (6.1, 17.1)
Per 20% of time CD4 <200 cells/µLb … 1.39 (1.29, 1.49) … 1.36 (1.28, 1.43) … 1.46 (1.35, 1.58)
Global P value (AIC)c … <.0001 (2572) … <.0001 (2591) … <.0001 (2575)
CD4 count nadir, cells/µL
 <50 45 12.6 (6.1, 26.0) 61 7.0 (4.4, 11.2) 54 22.9 (7.1, 73.9)
50 to <100 17 5.5 (2.4, 12.5) 34 4.5 (2.7, 7.6) 20 11.2 (3.3, 37.7)
100 to <200 35 4.1 (1.9, 8.5) 77 3.8 (2.4, 6.0) 35 7.6 (2.3, 24.8)
200 to <350 49 3.2 (1.6, 6.6) 80 2.2 (1.4, 3.5) 47 6.5 (2.0, 20.9)
350 to <500 15 1.5 (0.6, 3.4) 42 1.6 (1.0, 2.6) 11 2.6 (0.7, 9.4)
 ≥500 9 1.0 (ref) 26 1.0 (ref) 3 1.0 (ref)
Per 50 cells/µLb … 0.82 (0.78, 0.86) … 0.85 (0.82, 0.88) … 0.79 (0.75, 0.84)
 Global P value (AIC)c … <.0001 (2564) … <.0001 (2583) … <.0001 (2562)
HIV RNA level average, copies/mL
 ≤500 47 1.0 (ref) 122 1.0 (ref) 44 1.0 (ref)
>500 to <10 000 41 1.2 (0.8, 1.9) 81 1.3 (1.0, 1.8) 51 1.4 (0.9, 2.1)
10 000 to <100 000 61 2.4 (1.6, 3.5) 88 1.9 (1.4, 2.5) 59 2.2 (1.5, 3.3)
 ≥100 000 21 5.3 (3.1, 8.9) 29 3.6 (2.4, 5.5) 16 5.4 (3.0, 9.8)
Per log10 copies/mLb … 1.58 (1.36, 1.84) … 1.36 (1.23, 1.52) … 1.56 (1.33, 1.83)
 Global P value (AIC)c … <.0001 (2607) … .0001 (2628) … <.0001 (2617)
Proportion of time HIV RNA level >500 copies/mL
 0.00 31 1.0 (ref) 95 1.0 (ref) 25 1.0 (ref)
>0.00 to 0.25 29 1.6 (0.9, 2.6) 51 1.2 (0.8, 1.7) 42 1.6 (1.0, 2.7)
>0.25 to 0.50 19 1.6 (0.9, 2.8) 49 1.8 (1.3, 2.6) 24 1.5 (0.9, 2.7)
>0.50 to 0.75 21 1.8 (1.0, 3.2) 47 1.9 (1.3, 2.8) 32 2.4 (1.4, 4.1)
>0.75 to <1.00 40 3.1 (1.9, 5.1) 57 2.2 (1.6, 3.2) 41 3.7 (2.2, 6.4)
1.00 30 2.5 (1.5, 4.3) 21 0.9 (0.6, 1.5) 6 1.8 (0.7, 4.5)
Per 20% of time HIV RNA >500 copies/mLb … 1.21 (1.11, 1.31) … 1.11 (1.04, 1.18) … 1.25 (1.14, 1.37)
Global P value (AIC)c … .0002 (2629) … .0001 (2627) … <.0001 (2625)
HIV RNA level peak, copies/mL
 ≤500 31 1.0 (ref) 95 1.0 (ref) 25 1.0 (ref)
>500 to <10 000 24 1.2 (0.7, 2.0) 44 1.0 (0.7, 1.4) 23 1.3 (0.7, 2.2)
10 000 to <100 000 54 1.9 (1.2, 3.0) 92 1.6 (1.2, 2.1) 54 1.9 (1.1, 3.0)
≥100 000 61 3.2 (2.1, 5.1) 89 2.3 (1.7, 3.1) 68 2.8 (1.7, 4.5)
Per log10 copies/mLb … 1.49 (1.30, 1.70) … 1.30 (1.19, 1.43) … 1.43 (1.25, 1.64)
Global P value (AIC)c … <.0001 (2615) … .0001 (2628) … <.0001 (2626)
Abbreviations: AIC, Akaike information criterion; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio. 
aEach measure was individually included in a cohort-stratified Cox model adjusted for sex, race/ethnicity, and baseline age and calendar period. The N and number of anal cancer cases for 
each moving window was: early (N = 34 625; number of anal cancer cases = 170), late (60 006; 320), and overall (34 625; 170).
bPtrend < .0001, except for early proportion of time HIV RNA level >500 copies/mL (Ptrend = .0010).
cGlobal P value and AIC from models among persons with follow-up >3060 days (N = 34 625; number of anal cancer cases = 170).
then ART would have little preventive effect if initiated late, once 
immunosuppression has already played its main role of promoting 
HSIL/AIN2-3 [4]. Presumably a high proportion of persons who 
initiated ART at the start of the ART era already had experienced 
severe, prolonged immunosuppression, likely explaining the lack 
of decline in anal cancer incidence at that time [2, 7–15]. The trend 
toward earlier ART initiation since then [37] might explain the ap-
parent decreasing incidence since 2008 [1, 2].
Nevertheless, anal cancer risk remains markedly elevated 
in PLWH [1], so optimization of prevention and screening 
efforts are needed. Early HIV diagnosis and prompt ART 
initiation [38, 39] could prevent the severe, prolonged im-
munosuppression associated with increased anal cancer risk. 
Vaccination against oncogenic HPV infection, especially 
among young MSM, and smoking cessation could also re-
duce risk and merit incorporation into primary HIV care 
Table 5. Best CD4 Count and Human Immunodeficiency Virus RNA Level Predictors and Final Model for Anal Cancer Risk, North American AIDS Cohort 







Model 1 (Final 
Model) Model 2 Model 3 Model 4
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Overall CD4 count nadir, cells/µLc
 <50 54 22.9 (7.1, 73.9) 13.4 (3.5, 51.0) 18.4 (5.5, 61.7) … 11.7 (3.0, 46.1)
50 to <100 20 11.2 (3.3, 37.7) 8.1 (2.1, 31.2) 10.1 (2.9, 35.0) … 7.9 (2.0, 31.0)
100 to <200 35 7.6 (2.3, 24.8) 6.2 (1.7, 22.2) 7.3 (2.2, 24.0) … 6.1 (1.7, 22.2)
200 to <350 47 6.5 (2.0, 20.9) 6.5 (2.0, 20.9) 6.4 (2.0, 20.8) … 6.4 (2.0, 20.9)
350 to <500 11 2.6 (0.7, 9.4) 2.6 (0.7, 9.4) 2.6 (0.7, 9.4) … 2.6 (0.7, 9.4)
 ≥500 3 1.0 (ref) 1.0 (ref) 1.0 (ref) … 1.0 (ref)
 Global P value … <.0001 <.0001 <.0001 … <.0001
Per 50 cells/µL … 0.79 (0.75, 0.84) 0.85 (0.79, 0.92) 0.82 (0.77, 0.87) … 0.87 (0.80, 0.93)
  Ptrend … <.0001 <.0001 <.0001 … .0002
 AIC … 2562 … … … …
Early proportion of time 
CD4 count <200 cells/µLd
 0.00 73 1.0 (ref) 1.0 (ref) … 1.0 (ref) 1.0 (ref)
>0.00 to 0.25 29 2.1 (1.4, 3.3) 1.4 (0.7, 2.7) … 1.9 (1.2, 2.9) 1.3 (0.7, 2.6)
>0.25 to 0.50 12 2.1 (1.1, 3.8) 1.1 (0.5, 2.5) … 1.7 (0.9, 3.2) 1.1 (0.5, 2.4)
>0.50 to 0.75 10 2.2 (1.2, 4.3) 1.1 (0.4, 2.6) … 1.8 (0.9, 3.5) 1.0 (0.4, 2.4)
>0.75 to <1.00 9 2.1 (1.1, 4.3) 0.9 (0.4, 2.3) … 1.6 (0.8, 3.3) 0.9 (0.3, 2.2)
1.00 37 7.9 (5.3, 11.9) 3.1 (1.5, 6.6) … 5.8 (3.7, 9.1) 2.9 (1.4, 6.1)
Global P value … <.0001 .0009 … <.0001 .0015
Per 20% of time CD4 <200 cells/µL … 1.39 (1.29, 1.49) 1.17 (1.05, 1.29) … 1.31 (1.20, 1.42) 1.15 (1.04, 1.28)
 Ptrend … <.0001 .0030 … <.0001 .0065
AIC … 2572 … … … …
Early HIV RNA level 
average, copies/mLd
 ≤500 47 1.0 (ref) … 1.0 (ref) 1.0 (ref) 1.0 (ref)
>500 to <10 000 41 1.2 (0.8, 1.9) … 0.9 (0.6, 1.3) 1.1 (0.7, 1.6) 0.9 (0.6, 1.3)
10 000 to <100 000 61 2.4 (1.6, 3.5) … 1.2 (0.8, 1.8) 1.6 (1.0, 2.4) 1.2 (0.7, 1.8)
≥100 000 21 5.3 (3.1, 8.9) … 1.9 (1.0, 3.4) 2.5 (1.4, 4.5) 1.7 (0.9, 3.2)
Global P value … <.0001 … .089 .014 .15
Per log10 copies/mL … 1.58 (1.36, 1.84) … 1.17 (0.99, 1.39) 1.28 (1.09, 1.51) 1.14 (0.96, 1.35)
 Ptrend … <.0001 … .064 .0030 .15
AIC … 2607 … … … …
Combined models’ AIC … 2551 2561 2567 2551
Abbreviations: AIC, Akaike information criterion; CI, confidence interval; HR, hazard ratio; HIV, human immunodeficiency virus. 
aEach measure was individually included in a cohort-stratified Cox model adjusted for sex, race/ethnicity, and baseline age and calendar period among persons with follow-up >3060 days 
(N = 34 625; number of anal cancer cases = 170).
bFrom cohort-stratified Cox model with combinations of key predictors as covariates and adjusted for sex, race/ethnicity, and baseline age and calendar period among persons with follow-up 
>3060 days.
cCD4 count nadir from 3060 to 180 days (approximately 8.5 years to approximately 6 months) in the past.
dProportion of time CD4 count <200 cells/µL and HIV RNA level average from 3060 to 1620 days (approximately 8.5 to approximately 4.5 years) in the past.
[39]. Furthermore, a firm evidence base needs to be de-
veloped for HSIL/AIN2-3 screening and management in 
PLWH [39, 40]. Anal cancer screening may be more effective 
if targeted to high-risk subgroups such as MSM, especially 
young MSM with AIDS [2]. Nadir and cumulative CD4, 
along with having a prior AIDS diagnosis (a proxy for low 
CD4 nadir), may represent useful markers for identifying 
patients at higher risk for anal cancer to target for screening 
and other prevention efforts.
Our study’s limitations included a lack of information on anal 
HPV infection (including HPV genotype), anal intercourse fre-
quency (a risk factor for HPV infection), presence of anal warts 
(an indicator of HPV infection), and anal cancer screening. 
HIV risk group and smoking data were incomplete; never-
theless, adjusting for these variables in sensitivity analyses re-
vealed that our final model was highly robust. Furthermore, our 
study included a low percentage of females and Hispanics and 
only US and Canadian populations, limiting generalizability. 
Finally, none of the examined CD4 or HIV RNA measures fully 
characterize HIV-associated immune dysfunction (before or 
after ART).
Our study’s strengths included large sample size and number 
of events, coverage across 19 years during the ART era among 
people with varied characteristics and from diverse North 
American locations, validated anal cancer diagnoses, and com-
prehensive evaluation of various CD4 and HIV RNA measures, 
capturing exposures that occurred as far back as approximately 
8.5 years. Our approach of examining cumulative and nadir/peak 
measures during moving windows of fixed duration may be su-
perior to examining these measures during total follow-up time, 
which varies by person.
In summary, we found CD4 nadir from approximately 
8.5 years to approximately 6 months in the past and cumulative 
CD4 (ie, proportion of time CD4 <200 cells/µL) from approxi-
mately 8.5 to approximately 4.5 years in the past, in combination, 
to be the most robust independent predictors of anal cancer risk. 
Besides capturing severity of immunosuppression during the ap-
proximately 8-year window, CD4 nadir likely also captured cu-
mulative immunosuppression. As evidence suggested that CD4 
in the early part of the window had the greatest influence on 
risk, our results were consistent with severe, prolonged immu-
nosuppression affecting the earlier stages in anal carcinogen-
esis. Initiating ART promptly upon HIV diagnosis, as currently 
recommended [38], and monitoring nadir and cumulative CD4 
to help target prevention efforts may be important for anal 
cancer prevention in PLWH.
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